OTCMKTS:AVCTF Avacta Group (AVCTF) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free AVCTF Stock Alerts $0.59 0.00 (0.00%) (As of 04/25/2024 ET) Add Compare Share Share Today's Range$0.59▼$0.5950-Day Range$0.59▼$1.6252-Week Range$0.59▼$2.17Volume110 shsAverage Volume2,773 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartShort InterestStock AnalysisChartShort Interest Get Avacta Group alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Avacta Group Stock (OTCMKTS:AVCTF)Avacta Group Plc develops cancer therapies and diagnostics in the United Kingdom, France, North America, South Korea, and rest of Asia and Europe. The company operates through Diagnostics and Therapeutics segments. It develops products based on its proprietary Affimer and pre|CISION technology platforms. The company develops AVA6000, FAPa-activated doxorubicin that is in Phase I clinical trial for treating locally advanced or metastatic-selected solid tumors; AVA3996, a tumor-targeted proteasome inhibitor based on bortezomib; AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing LR19128 PD-L1 XT; and collaboration and license agreement with Avacta and Daewoong Pharmaceutical Co. Ltd. for developing AFX-001 for solid organ transplant and graft vs host Disease, and AFX-002 for multiple sclerosis. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.Read More AVCTF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AVCTF Stock News HeadlinesApril 5, 2024 | finance.yahoo.comAvacta Group - AVA6000 Abstract Release by AACR and Full Presentation UpdateApril 4, 2024 | morningstar.comAvacta Group PLC AVCTFApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? November 11, 2023 | morningstar.comAvacta Group PLC AVCTNovember 8, 2023 | finance.yahoo.comAvacta Group's (LON:AVCT) growing losses don't faze investors as the stock soars 11% this past weekOctober 5, 2023 | finance.yahoo.comAvacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsSeptember 7, 2023 | finance.yahoo.comAvacta Group Plc (LON:AVCT) is largely controlled by institutional shareholders who own 53% of the companyJune 5, 2023 | lse.co.ukAvacta sees shares rise on new equity payment for South Korea ventureApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? June 1, 2023 | finance.yahoo.comAvacta Group's (LON:AVCT) investors will be pleased with their solid 218% return over the last five yearsMay 5, 2023 | finance.yahoo.comAvacta Group Plc's (LON:AVCT) Business Is Trailing The Industry But Its Shares Aren'tApril 7, 2023 | marketwatch.comAvacta Group's Shares Rise on US Site Openings for Cancer Study Patient EnrolmentApril 6, 2023 | lse.co.ukAvacta doses first patient in fifth cohort of AVA6000 phase 1 studyApril 6, 2023 | lse.co.ukAvacta opens first two clinical investigator sites in US for AVA6000April 5, 2023 | finance.yahoo.comAvacta Announces First Patient Dosed in Fifth Cohort of AVA6000 Phase Ia Dose Escalation StudyApril 1, 2023 | finance.yahoo.comAvacta to Present Pre-Clinical Data on AVA3996 at the American Association for Cancer Research Annual MeetingMarch 31, 2023 | finanznachrichten.deAvacta Group plc: Avacta Appoints Karen Harrison as Chief Operating Officer for Therapeutics DivisionMarch 31, 2023 | finance.yahoo.comAvacta Group Plc (LON:AVCT) is favoured by institutional owners who hold 55% of the companyJanuary 17, 2023 | benzinga.comAvacta Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical StudyDecember 1, 2022 | finance.yahoo.comInvestors in Avacta Group (LON:AVCT) have made a incredible return of 538% over the past three yearsSeptember 11, 2022 | fool.co.ukAvacta GroupSeptember 5, 2022 | finance.yahoo.comAvacta Announces AVA6000 Receives Orphan Drug Designation From the US Food and Drug AdministrationSeptember 1, 2022 | finance.yahoo.comAvacta Announces Phase I Clinical Study of AVA6000 to Advance to the Fourth CohortMay 3, 2022 | finance.yahoo.comEven though Avacta Group (LON:AVCT) has lost UK£39m market cap in last 7 days, shareholders are still up 304% over 3 yearsApril 13, 2022 | finance.yahoo.comAvacta Announces AffyXell Joint Venture Milestone and Increased Equity StakeJanuary 18, 2022 | finance.yahoo.comWhat You Need To Know About Avacta Group Plc's (LON:AVCT) Investor CompositionNovember 29, 2021 | finance.yahoo.comAvacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000See More Headlines Receive AVCTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avacta Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:AVCTF CUSIPN/A CIKN/A Webwww.avacta.com Phone44.1904.21.7070FaxN/AEmployees120Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. David Alastair Maclaughlin Smith (Age 58)CEO & Executive Director Comp: $560.66kMr. Tony Gardiner (Age 53)CFO, Company Secretary & Executive Director Comp: $344.73kDr. Christina Marie Coughlin B.S. (Age 54)M.D., Ph.D., Head of Research & Development, Interim Chief Medical Officer and Director Comp: $46.72kMs. Emma WrightGroup In-House CounselMr. Michael VinegradGroup Communications DirectorMr. R. Craig Slater FCA (Age 60)Chief Operating Officer of Diagnostics Comp: $87.13kDr. Matt JohnsonChief Scientific Officer of DiagnosticsDr. Fiona McLaughlin FSB (Age 54)Ph.D., Chief Scientific Officer of Therapeutics Division Mr. David WilsonChief Commercial Officer of DiagnosticsMs. Karen HarrisonChief Operating Officer of Therapeutics DivisionMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AVCTF Stock Analysis - Frequently Asked Questions How have AVCTF shares performed in 2024? Avacta Group's stock was trading at $1.62 at the start of the year. Since then, AVCTF stock has decreased by 63.6% and is now trading at $0.59. View the best growth stocks for 2024 here. Are investors shorting Avacta Group? Avacta Group saw a decrease in short interest during the month of April. As of April 15th, there was short interest totaling 229,200 shares, a decrease of 17.8% from the March 31st total of 278,900 shares. Based on an average daily trading volume, of 200 shares, the days-to-cover ratio is currently 1,146.0 days. View Avacta Group's Short Interest. How do I buy shares of Avacta Group? Shares of AVCTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:AVCTF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
